- Home
- DBVT vs ATAI Comparison
DBVT vs ATAI Comparison
Compare DBVT & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- ATAI
- Stock Information
- Founded
- DBVT 2002
- ATAI 2018
- Country
- DBVT France
- ATAI Germany
- Employees
- DBVT N/A
- ATAI N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- DBVT Health Care
- ATAI Health Care
- Exchange
- DBVT Nasdaq
- ATAI Nasdaq
- Market Cap
- DBVT 239.9M
- ATAI 282.6M
- IPO Year
- DBVT N/A
- ATAI 2021
- Fundamental
- Price
- DBVT $8.01
- ATAI $2.47
- Analyst Decision
- DBVT Buy
- ATAI Strong Buy
- Analyst Count
- DBVT 4
- ATAI 3
- Target Price
- DBVT $14.81
- ATAI $10.50
- AVG Volume (30 Days)
- DBVT 102.2K
- ATAI 2.2M
- Earning Date
- DBVT 07-29-2025
- ATAI 05-14-2025
- Dividend Yield
- DBVT N/A
- ATAI N/A
- EPS Growth
- DBVT N/A
- ATAI N/A
- EPS
- DBVT N/A
- ATAI N/A
- Revenue
- DBVT $3,497,000.00
- ATAI $1,863,000.00
- Revenue This Year
- DBVT $1,700.53
- ATAI $242.21
- Revenue Next Year
- DBVT $535.67
- ATAI N/A
- P/E Ratio
- DBVT N/A
- ATAI N/A
- Revenue Growth
- DBVT N/A
- ATAI 572.56
- 52 Week Low
- DBVT $2.21
- ATAI $1.03
- 52 Week High
- DBVT $12.78
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- DBVT 41.18
- ATAI 78.86
- Support Level
- DBVT $8.33
- ATAI $2.18
- Resistance Level
- DBVT $9.92
- ATAI $2.38
- Average True Range (ATR)
- DBVT 0.86
- ATAI 0.19
- MACD
- DBVT -0.34
- ATAI 0.07
- Stochastic Oscillator
- DBVT 1.48
- ATAI 88.09
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.